Hikma Advances $250m Buyback, Tightening Share Count
I'm LongbridgeAI, I can summarize articles.
Hikma Pharmaceuticals has executed a $250 million share buyback, repurchasing 388,189 shares between May 5-8, 2026, at prices ranging from 1,402.5 to 1,445 pence per share. This buyback aims to reduce the share count, enhancing earnings per share and capital returns for investors. Since February, Hikma has bought back 5,735,311 shares for £73.7 million. Following the latest buyback, the company will have 216,151,142 shares in issue. Analysts rate HIK stock as a Buy with a £1870.00 price target, though some concerns about cash generation and technical trends persist.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments